Industry News
Pharmaceutical Industry News
Texas Senate Passes Bill to Crack Down on Mail-Order Abortion Pills
Gov. Greg Abbott is expected to sign the legislation, which allows nearly anyone to sue abortion medication providers and distributors.
F.D.A. Official Overruled Scientists on Wide Access to Covid Shots
The agency’s staff scientists pointed out how Covid was still unpredictable and posed a threat to toddlers, but the official decided to restrict shots only to children with risk factors.
Point of Care revenue surpassed…
Point of Care revenue surpassed $1B in 2024—see why it’s becoming a cornerstone of healthcare media strategies.
A new awareness-raising effort…
A new awareness-raising effort from Incyte is aimed at giving doctors an up-close look at the emotional and physical challenges their patients with hidradenitis suppurativa face.
Ori Biotech has lassoed a…
Ori Biotech has lassoed a significant milestone for its cell and gene therapy manufacturing platform, IRO, which now boasts a coveted Advanced Manufacturing Technology designation from the FDA.
After joining multiple other…
After joining multiple other drugmakers on the U.S. investment bandwagon earlier this year, Gilead Sciences is providing further details on where it plans to channel its $32 billion pledge.
The drug manufacturer lobby’s…
The drug manufacturer lobby's seven-figure campaign, set to run through the end of the year, portrays fictional nonprofit hospital leaders celebrating profits derived from the program's discounts.
The move forms the next step in…
The move forms the next step in the company's long-held plan to exit manufacturing operations in India, with its Bangalore site expected to cease operations over the 2025-2026 Indian fiscal year.
The UK is losing business…
The UK is losing business opportunities in the life sciences sector because the government undervalues the economic and social benefits of investing in the manufacturing of innovative medicines, according to a report from the Cambridge
Paul Offit, M.D., a prominent…
Paul Offit, M.D., a prominent vaccine expert who has also become a vocal critic of HHS secretary Robert F. Kennedy Jr., can no longer participate on the FDA’s Vaccines and Related Biological Products Advisory Committee
BD is putting a fresh spin on an…
BD is putting a fresh spin on an old awareness drive, returning to the 12-year-old “Love Your Limbs” campaign to mark Peripheral Artery Disease Awareness Month.
Trump Wants Proof That Covid Vaccines Work. It’s Easy to Find.
In a post on Truth Social, the president suggested that the C.D.C. was being “ripped apart” over a question that was answered long ago.
The “Check for Cancer”…
The “Check for Cancer” campaign, which launched Wednesday, connects the common checkerboard pattern to the concept of undergoing regular cancer screenings.
More than three years after…
More than three years after launching a new corporate structure, Novartis is still making changes to its organization.
United’s share price surged by…
United's share price surged by more than 33% by Tuesday afternoon with what the company's SVP of product development Peter Smith called "overwhelmingly positive" phase 3 results in idiopathic pulmonary fibrosis.
Dr. Jeffrey Allen discusses the…
Dr. Jeffrey Allen discusses the need for shared clinical language, patient input and new treatment approaches for chronic inflammatory demyelinating polyneuropathy.
In a Q&A for Fierce Pharma…
In a Q&A for Fierce Pharma Marketing’s “Rising Stars” series, Biles discussed the importance of empathy in her work and her vision for a more all-encompassing depiction of the patient experience in pharma ads.
Ionis has hit a “home run,”…
Ionis has hit a “home run,” according to analysts at Citi, with data in two phase 3 trials that show the ability of Tryngolza to reduce triglycerides and acute pancreatitis events in individuals with severe
Verquvo failed to deliver a…
Verquvo failed to deliver a composite cardiovascular benefit for certain patients with heart failure, with investigators noting seemingly divergent results on two key measures.
While a recent head-to-head trial…
While a recent head-to-head trial of the obesity med heavyweights Wegovy and Zepbound favored the latter drug from Eli Lilly on weight loss, Novo Nordisk has now countered that result with Zepbound-topping data in another